The industry's decision to enthusiastically welcome the report means it has lost the opportunity to trade off the savings pathway for unambiguous improvements in access to therapies providing superior patient outcomes. …
A response that risks upfront acceptance of changes to deliver billions in new savings
September 11, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Wesfarmers Health announces plan to build new fulfilment centre in Cairns
September 17, 2024 - - Latest News -
Medicines Australia launches next phase of campaign in PM's electorate
September 17, 2024 - - Latest News -
The HTA Review report - 'Red Flag' number three of five
September 17, 2024 - - Latest News -
Immutep says its candidate in combination with Keytruda delivered positive efficacy and safety profile
September 16, 2024 - - Latest News -
Medicines Australia responds to questions on the HTA Review
September 16, 2024 - - Latest News -
The HTA Review report - 'Red Flag' number two of five
September 16, 2024 - - Latest News -
Australian company Kazia executes licensing agreement with QIMR Berghofer
September 16, 2024 - - Latest News